Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

The safety and efficacy of EGF-based cream for the prevention of radiotherapy-induced skin injury: results from a multicenter observational study

  • Kang, Hyun-Cheol (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Ahn, Seung-Do (Department of Radiation Oncology, Asan Medical Center) ;
  • Choi, Doo-Ho (Department of Radiation Oncology, Samsung Medical Center) ;
  • Kang, Min Kyu (Department of Radiation Oncology, Yeungnam University College of Medicine) ;
  • Chung, Woong-Ki (Department of Radiation Oncology, Chonnam National University Hwasun Hospital) ;
  • Wu, Hong-Gyun (Department of Radiation Oncology, Seoul National University College of Medicine)
  • Received : 2014.03.24
  • Accepted : 2014.08.11
  • Published : 2014.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: This study was designed to evaluate the efficacy and safety of topically applied recombinant human epidermal growth factor (rhEGF) for the prevention of radiation-induced dermatitis in cancer patients. Materials and Methods: From December 2010 to April 2012, a total of 1,172 cancer patients who received radiotherapy (RT) of more than 50 Gy were prospectively enrolled and treated with EGF-based cream. An acute skin reaction classified according to the Radiation Therapy Oncology Group 6-point rating scale was the primary end point and we also assessed the occurrence of edema, dry skin, or pruritus. Results: The percentage of radiation dermatitis with maximum grade 0 and grade 1 was 19% and 58% at the time of 50 Gy, and it became 29% and 47% after completion of planned RT. This increment was observed only in breast cancer patients (from 18%/62% to 32%/49%). Adverse events related to the EGF-based cream developed in 49 patients (4%) with mild erythema the most common. Skin toxicity grade >2 was observed in 5% of the patients. Edema, dry skin, and pruritus grade ${\geq}3$ developed in 9%, 9%, and 1% of the patients, respectively. Conclusion: Prophylactic use of an EGF-based cream is effective in preventing radiation dermatitis with tolerable toxicity. Further studies comparing EGF cream with other topical agents may be necessary.

Keywords

References

  1. Harper JL, Franklin LE, Jenrette JM, Aguero EG. Skin toxicity during breast irradiation: pathophysiology and management. South Med J 2004;97:989-93. https://doi.org/10.1097/01.SMJ.0000140866.97278.87
  2. Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol 2006;54:28-46. https://doi.org/10.1016/j.jaad.2005.08.054
  3. Pignol JP, Olivotto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 2008;26:2085-92. https://doi.org/10.1200/JCO.2007.15.2488
  4. Fisher J, Scott C, Stevens R, et al. Randomized phase III study comparing Best Supportive Care to Biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation: Radiation Therapy Oncology Group (RTOG) 97-13. Int J Radiat Oncol Biol Phys 2000;48:1307-10. https://doi.org/10.1016/S0360-3016(00)00782-3
  5. Lee SY, Kwon HC, Kim JS, Lee HK. An analysis of the incidence and related factors for radiation dermatitis in breast cancer patients who received radiation therapy. J Korean Soc Ther Radiol Oncol 2010;28:16-22. https://doi.org/10.3857/jkstro.2010.28.1.16
  6. Bolderston A, Lloyd NS, Wong RK, Holden L, Robb-Blenderman L; Supportive Care Guidelines Group of Cancer Care Ontario Program in Evidence-Based Care. The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. Support Care Cancer 2006;14:802-17. https://doi.org/10.1007/s00520-006-0063-4
  7. Lee SW, Jung KI, Kim YW, Jung HD, Kim HS, Hong JP. Effect of epidermal growth factor against radiotherapy-induced oral mucositis in rats. Int J Radiat Oncol Biol Phys 2007;67:1172-8. https://doi.org/10.1016/j.ijrobp.2006.10.038
  8. Ryu SH, Kim YH, Lee SW, Hong JP. The preventive effect of recombinant human growth factor (rhEGF) on the recurrence of radiodermatitis. J Radiat Res 2010;51:511-7. https://doi.org/10.1269/jrr.10010
  9. Wu HG, Song SY, Kim YS, et al. Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: a double-blind placebocontrolled prospective phase 2 multi-institutional clinical trial. Cancer 2009;115:3699-708. https://doi.org/10.1002/cncr.24414
  10. Denham JW, Hauer-Jensen M. The radiotherapeutic injury: a complex 'wound'. Radiother Oncol 2002;63:129-45. https://doi.org/10.1016/S0167-8140(02)00060-9
  11. Olascoaga A, Vilar-Compte D, Poitevin-Chacon A, Contreras- Ruiz J. Wound healing in radiated skin: pathophysiology and treatment options. Int Wound J 2008;5:246-57. https://doi.org/10.1111/j.1742-481X.2008.00436.x
  12. Haubner F, Ohmann E, Pohl F, Strutz J, Gassner HG. Wound healing after radiation therapy: review of the literature. Radiat Oncol 2012;7:162. https://doi.org/10.1186/1748-717X-7-162
  13. Hong JP, Jung HD, Kim YW. Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers. Ann Plast Surg 2006;56:394-400. https://doi.org/10.1097/01.sap.0000198731.12407.0c
  14. Chan RJ, Larsen E, Chan P. Re-examining the evidence in radiation dermatitis management literature: an overview and a critical appraisal of systematic reviews. Int J Radiat Oncol Biol Phys 2012;84:e357-62. https://doi.org/10.1016/j.ijrobp.2012.05.009
  15. Zhang Y, Zhang S, Shao X. Topical agent therapy for prevention and treatment of radiodermatitis: a meta-analysis. Support Care Cancer 2013;21:1025-31. https://doi.org/10.1007/s00520-012-1622-5
  16. Schmuth M, Wimmer MA, Hofer S, et al. Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study. Br J Dermatol 2002;146:983-91. https://doi.org/10.1046/j.1365-2133.2002.04751.x
  17. Pommier P, Gomez F, Sunyach MP, D'Hombres A, Carrie C, Montbarbon X. Phase III randomized trial of Calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer. J Clin Oncol 2004;22:1447-53. https://doi.org/10.1200/JCO.2004.07.063
  18. Niazi TM, Vuong T, Azoulay L, et al. Silver clear nylon dressing is effective in preventing radiation-induced dermatitis in patients with lower gastrointestinal cancer: results from a phase III study. Int J Radiat Oncol Biol Phys 2012;84:e305-10. https://doi.org/10.1016/j.ijrobp.2012.03.062
  19. Kong M, Hong SE. Topical use of recombinant human epidermal growth factor (EGF)-based cream to prevent radiation dermatitis in breast cancer patients: a singleblind randomized preliminary study. Asian Pac J Cancer Prev 2013;14:4859-64. https://doi.org/10.7314/APJCP.2013.14.8.4859
  20. Elliott EA, Wright JR, Swann RS, et al. Phase III Trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13. J Clin Oncol 2006;24:2092-7. https://doi.org/10.1200/JCO.2005.04.9148
  21. Choi J, Moon SY, Hong JP, Song JY, Oh KT, Lee SW. Epidermal growth factor induces cell death in the absence of overexpressed epidermal growth factor receptor and ErbB2 in various human cancer cell lines. Cancer Invest 2010;28:505-14. https://doi.org/10.3109/07357900902783179
  22. Geissler C, Hambek M, Eckardt A, et al. The role of recombinant epidermal growth factor and serotonin in the stimulation of tumor growth in a SCCHN xenograft model. Oncol Rep 2012;28:785-90. https://doi.org/10.3892/or.2012.1903
  23. Ozawa S, Ueda M, Ando N, Abe O, Hirai M, Shimizu N. Stimulation by EGF of the growth of EGF receptor-hyperproducing tumor cells in athymic mice. Int J Cancer 1987;40:706-10. https://doi.org/10.1002/ijc.2910400523
  24. Ginsburg E, Vonderhaar BK. Epidermal growth factor stimulates the growth of A431 tumors in athymic mice. Cancer Lett 1985;28:143-50. https://doi.org/10.1016/0304-3835(85)90069-2
  25. Berlanga-Acosta J, Gavilondo-Cowley J, Lopez-Saura P, et al. Epidermal growth factor in clinical practice: a review of its biological actions, clinical indications and safety implications. Int Wound J 2009;6:331-46. https://doi.org/10.1111/j.1742-481X.2009.00622.x
  26. Schmuth M, Sztankay A, Weinlich G, et al. Permeability barrier function of skin exposed to ionizing radiation. Arch Dermatol 2001;137:1019-23.

Cited by

  1. The Efficacy and Safety of Jaungo, a Traditional Medicinal Ointment, in Preventing Radiation Dermatitis in Patients with Breast Cancer: A Prospective, Single-Blinded, Randomized Pilot Study vol.2016, pp.None, 2014, https://doi.org/10.1155/2016/9481413
  2. MDP: A Deinococcus Mn 2+ -Decapeptide Complex Protects Mice from Ionizing Radiation vol.11, pp.8, 2014, https://doi.org/10.1371/journal.pone.0160575
  3. Prevention and treatment of radiation-induced acute dermatitis in head and neck cancer patients: a systematic review vol.14, pp.3, 2014, https://doi.org/10.2217/fon-2017-0359
  4. Topical atorvastatin 1% for prevention of skin toxicity in patients receiving radiation therapy for breast cancer: a randomized, double-blind, placebo-controlled trial vol.75, pp.2, 2014, https://doi.org/10.1007/s00228-018-2570-x
  5. A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor‐Induced Skin Toxicities vol.25, pp.1, 2020, https://doi.org/10.1634/theoncologist.2019-0221
  6. 방사선 피부염 치료법에 대한 문헌고찰 vol.25, pp.1, 2014, https://doi.org/10.15432/jkto.2020.25.1.011
  7. Radiation-induced skin injury: pathogenesis, treatment, and management vol.12, pp.22, 2014, https://doi.org/10.18632/aging.103932